Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal Article
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
TL;DR: The ability of leukemic cell lines to regulate cell cycle progression and to trigger apoptosis is more indicative of their sensitivity to topoisomerase poisons than cleavable complexes induced by these drugs.
Journal ArticleDOI
Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells.
Philippe Pourquier,Yuji Takebayashi,Yoshimasa Urasaki,Christopher Gioffre,Glenda Kohlhagen,Yves Pommier +5 more
TL;DR: The observed inhibition of religation at the ara-C site suggests the importance of the alignment of the 5'-hydroxyl end for religation with the phosphate group of the top1 phosphotyrosine bond.
Journal ArticleDOI
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.
Joshua O. Ojwang,Robert W. Buckheit,Yves Pommier,Abhijit Mazumder,K De Vreese,José A. Esté,D. Reymen,Luke A. Pallansch,Carol Lackman-Smith,T L Wallace +9 more
TL;DR: The ability of T 30177 to inhibit both laboratory and clinical isolates of HIV-1 and the experimental data which suggest that T30177 represents a novel class of integrase inhibitors indicate that this compound is a viable candidate for evaluation as a therapeutic agent against HIV- 1 in humans.
Journal ArticleDOI
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.
Vinodh N. Rajapakse,Augustin Luna,Mihoko Yamade,Lisa Loman,Sudhir Varma,Margot Sunshine,Francesco Iorio,Fabricio G. Sousa,Fathi Elloumi,Mirit I. Aladjem,Anish Thomas,Chris Sander,Kurt W. Kohn,Cyril H. Benes,Mathew J. Garnett,William C. Reinhold,Yves Pommier +16 more
TL;DR: The value of CellMinerCDB in selecting drugs with reproducible activity is demonstrated, the dominant role of SLFN11 for drug response is expanded, and novel response determinants and genomic signatures for topoisomerase inhibitors and schweinfurthins are presented.
Journal ArticleDOI
Hydrazide-Containing Inhibitors of HIV-1 Integrase†
He Zhao,Nouri Neamati,Sanjay Sunder,Huixiao Hong,Shaomeng Wang,George W. A. Milne,Yves Pommier,Terrence R. Burke +7 more
TL;DR: In this paper, the authors used a three-point pharmacophore search based on its assigned structure N-(2-hydroxybenzoyl)-N-(2hydroxy-3-phenoxypropyl)hydrazine (1) to identify structural leads for the development of new HIV integrase inhibitors which do not rely on potentially cytotoxic catechol substructure.